Literature DB >> 29450841

Differential Binding of Human ApoE Isoforms to Insulin Receptor is Associated with Aberrant Insulin Signaling in AD Brain Samples.

Elizabeth S Chan1, Christopher Chen2,3, Tuck Wah Soong1,4, Boon-Seng Wong5,6.   

Abstract

Apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for sporadic Alzheimer's disease (AD), where inheritance of this isoform predisposes development of AD in a gene dose-dependent manner. Although the mode of action of ApoE4 on AD onset and progression remains unknown, we have previously shown that ApoE4, and not ApoE3 expression, resulted in insulin signaling deficits in the presence of amyloid beta (Aβ). However, these reports were not conducted with clinical samples that more accurately reflect human disease. In this study, we investigated the effect of ApoE genotype on the insulin signaling pathway in control and AD human brain samples. We found that targets of the insulin signaling pathway were attenuated in AD cases, regardless of ApoE isoform. We also found a decrease in GluR1 subunit expression, and an increase NR2B subunit expression in AD cases, regardless of ApoE isoform. Lastly, we observed that more insulin receptor (IR) was immunoprecipitated in control cases, and more Aβ was immunoprecipitated with AD cases. But, when comparing among AD cases, we found that more IR was immunoprecipitated with ApoE3 than ApoE4, and more Aβ was immunoprecipitated with ApoE4 than ApoE3. Our results suggest that the difference in IR binding and effect on protein expression downstream of the IR may affect onset and progression of AD.

Entities:  

Keywords:  Akt signaling; Alzheimer’s disease; Amyloid pathology; ApoE; Insulin signaling

Mesh:

Substances:

Year:  2018        PMID: 29450841     DOI: 10.1007/s12017-018-8480-3

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  56 in total

1.  Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction.

Authors:  Y Hayashi; S H Shi; J A Esteban; A Piccini; J C Poncer; R Malinow
Journal:  Science       Date:  2000-03-24       Impact factor: 47.728

2.  Amyloid beta oligomers induce impairment of neuronal insulin receptors.

Authors:  Wei-Qin Zhao; Fernanda G De Felice; Sara Fernandez; Hui Chen; Mary P Lambert; Michael J Quon; Grant A Krafft; William L Klein
Journal:  FASEB J       Date:  2007-08-24       Impact factor: 5.191

3.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Authors:  Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

4.  Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes.

Authors:  Na Zhao; Chia-Chen Liu; Alexandra J Van Ingelgom; Yuka A Martens; Cynthia Linares; Joshua A Knight; Meghan M Painter; Patrick M Sullivan; Guojun Bu
Journal:  Neuron       Date:  2017-09-27       Impact factor: 17.173

Review 5.  Positive and negative regulation of insulin signaling through IRS-1 phosphorylation.

Authors:  Philippe Gual; Yannick Le Marchand-Brustel; Jean-François Tanti
Journal:  Biochimie       Date:  2005-01       Impact factor: 4.079

6.  Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation.

Authors:  M G Myers; T C Grammer; L M Wang; X J Sun; J H Pierce; J Blenis; M F White
Journal:  J Biol Chem       Date:  1994-11-18       Impact factor: 5.157

7.  ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation.

Authors:  U Beffert; J Poirier
Journal:  Neuroreport       Date:  1998-10-05       Impact factor: 1.837

Review 8.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

9.  Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice.

Authors:  Elizabeth S Chan; Christopher Chen; Gregory M Cole; Boon-Seng Wong
Journal:  Sci Rep       Date:  2015-09-08       Impact factor: 4.379

10.  ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing Aβ impairment of insulin signaling in an Alzheimer's disease mouse model.

Authors:  Elizabeth S Chan; Mahesh Shivarama Shetty; Sreedharan Sajikumar; Christopher Chen; Tuck Wah Soong; Boon-Seng Wong
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

View more
  4 in total

1.  Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice.

Authors:  Andreas Giannisis; Kalicharan Patra; Anna K Edlund; Lur Agirrezabala Nieto; Joan Benedicto-Gras; Simon Moussaud; Andrés de la Rosa; Daniel Twohig; Tore Bengtsson; Yuan Fu; Guojun Bu; Greg Bial; Lander Foquet; Christina Hammarstedt; Stephen Strom; Kristina Kannisto; Jacob Raber; Ewa Ellis; Henrietta M Nielsen
Journal:  Mol Psychiatry       Date:  2022-04-13       Impact factor: 13.437

Review 2.  ApoE and cerebral insulin: Trafficking, receptors, and resistance.

Authors:  Elizabeth M Rhea; Jacob Raber; William A Banks
Journal:  Neurobiol Dis       Date:  2020-01-21       Impact factor: 5.996

Review 3.  Alzheimer's Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models.

Authors:  Maria Jose Carranza-Naval; Maria Vargas-Soria; Carmen Hierro-Bujalance; Gloria Baena-Nieto; Monica Garcia-Alloza; Carmen Infante-Garcia; Angel Del Marco
Journal:  Biomolecules       Date:  2021-02-10

Review 4.  The Blood-Brain Barrier, Oxidative Stress, and Insulin Resistance.

Authors:  William A Banks; Elizabeth M Rhea
Journal:  Antioxidants (Basel)       Date:  2021-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.